Thus, our data encourage further efforts to identify and validate HDAC inhibitors, as single agent or in combination, to induce maximal increase in CD38 expression to improve the efficacy of antibody and cellular immunotherapy in MM. Here, HDAC9 is linked to Miyoshi myopathy.